Thomas Benfield

Thomas Benfield

Principal Investigator: Thomas Benfield, Insitució/partner: (CREDID)

Group / Partner:

Professor of infectious diseases at the University of Copenhagen, attending physician at the Department of Infectious Diseases at Copenhagen University Hospital – Amager and Hvidovre, editor-in-chief of the Danish Medical Journal, and director of Center of Clinical Research & Disruption of Infectious Diseases (CREDID).

I am a scientist clinician with an interest in basic and clinical research covering HIV / AIDS, viral hepatitis, sepsis and pneumonia. These past years mostly COVID-19.

Recently or our research priorities have transformed from basic lab work and epidemiology to clinical trials. Our trial focus is on sepsis, pneumonia, hepatitis, HIV and COVID-19. The group serves as sponsor, investigator and subinvestigator of clinical phase I-III trials of antiretrovirals, antivirals, anti-inflammatory drugs and vaccines.

Over my career I have mentored 20+ PhD students and more than 30 graduate students.

Grant support past five years from Danish Regions, Ministry of Health, Capital Region of Denmark, Novo Nordisk Foundation, Pfizer, GSK, Simonsen’s Foundation and Lundbeck Foundation.

Clinical management of patients infected with sepsis, pneumonia, meningitis, tuberculosis, HIV, hepatitis B and C.

Clinical trial group established in 2006. Center of Clinical Research & Disruption of Infectious Diseases ( established 2020. CREDID is 7 PhD student, two post docs, four graduate students, three study nurses, a statistician, a technician and two coordinators. A team of 20 medical students assist with informed consent, enrollment, randomization, blinded and unblinded study tasks, CRF, and follow up of clinical trials.

Currently, I and CREDID sponsor three clinical trials. CREDID is currently involved in other investigator-initiated trials. Additionally, we collaborate with industry. Five phase III trials currently enrolling and three additional trials planned to open in 2022-24.